| Metabolic modulation of myocardial ischemia. | |
| | |
MedLine Citation:
|
PMID: 16524539 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The metabolic pathways of the heart during normoxia and ischemia have been well studied. High plasma fatty acid concentrations and the myocardial accumulation of long-chain fatty acyl metabolites during ischemia correlate with increased morbidity and mortality. However, enhanced glucose use can maintain cell homeostasis, diminish ischemic injury, and be clinically beneficial. Metabolic modulators represent a new class of drugs with the potential to treat myocardial ischemia. They are ideal as adjunctive anti-ischemic therapy because they lack the hemodynamic consequences of traditional therapy and treat the underlying metabolic dysfunction that leads to contractile failure and arrhythmias. Clinical studies have demonstrated their efficacy in acute and chronic settings. It is anticipated that there will be greater utilization of this new class of agents in the near future. |
| | |
Authors:
|
Sonal Jani; Steven R Bergmann |
Related Documents
:
|
7988089 - Silent infarction on a second ct scan in 91 patients without manifest stroke in the dut... 1535109 - Predictors of postoperative myocardial ischemia in patients undergoing noncardiac surge... 17049869 - Vacuum-assisted apical suction devices induce passive electrical changes consistent wit... 15749199 - Hypoxia inducible factor-1 expression mediates myocardial response to ischemia late aft... 19185369 - 2-dimensional strain echocardiography and early detection of myocardial ischemia. 17604959 - Three-dimensional evaluation of dobutamine-induced changes in regional myocardial defor... 10224569 - Effectiveness of continuous warm blood cardioplegia in cardiac valve re-replacement. 12972119 - Effectiveness of treatment of in-stent restenosis with an 8-french compatible atherecto... 20829509 - The atp-binding cassette transporter bcrp1/abcg2 plays a pivotal role in cardiac repair... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Current cardiology reports Volume: 8 ISSN: 1523-3782 ISO Abbreviation: Curr Cardiol Rep Publication Date: 2006 Mar |
Date Detail:
|
Created Date: 2006-03-09 Completed Date: 2007-09-24 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100888969 Medline TA: Curr Cardiol Rep Country: United States |
Other Details:
|
Languages: eng Pagination: 123-30 Citation Subset: IM |
Affiliation:
|
Division of Cardiology, Beth Israel Medical Center, Baird 5, 16th Street and First Avenue, New York, NY 10003, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Antagonists
/
pharmacology,
therapeutic use Enzyme Inhibitors / pharmacology, therapeutic use Fatty Acids / metabolism Glucose / metabolism, pharmacology, therapeutic use Humans Insulin / pharmacology, therapeutic use Lactates / metabolism Myocardial Ischemia / drug therapy, metabolism* Myocardium / metabolism*, pathology Oxidation-Reduction Potassium / pharmacology, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists; 0/Enzyme Inhibitors; 0/Fatty Acids; 0/Lactates; 0/glucose-insulin-potassium cardioplegic solution; 11061-68-0/Insulin; 50-99-7/Glucose; 7440-09-7/Potassium |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Advances in pharmacologic agents in imaging: new A2A receptor agonists.
Next Document: Imaging cardiac neuronal function and dysfunction.